Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cyxone (publ), a biotech in autoimmune diseases, announces that the company's Board has dismissed Tara Heitner from the company with immediate effect. Carl-Magnus Högerkorp, COO, will be acting as interim CEO.
Tara Heitner has been the CEO at Cyxone since 2020. During this time, she has successfully developed the company from a virtual lean research company to a growing company with several clinical development projects which are engaging potential licensing partners.
Carl-Magnus Högerkorp, COO and interim CEO at Cyxone, comments: "The company is currently facing an important phase in the development of the two drug candidates Rabeximod and T20K. At this point we are looking forward to the planned phase 2b study with Rabeximod in rheumatoid arthritis and to take the next steps in the preclinical and clinical development activities for T20K."
Bert Junno further comments: "It has been an intense and exciting time with Cyxone, and I am impressed of what Tara and her team have achieved during the past two years, even in very difficult times. Both Rabeximod and T20K are innovative projects with great potential to be developed into new treatments for large patient groups that today don't have any, or insufficient, treatment alternatives. I will continue to work actively with business development together with the company's new interim CEO Carl-Magnus Högerkorp who already is, in his role as COO, responsible for Cyxone's development programs."
Contact
Bert Junno, Chairman of the Board
Tel: +46 707 77 22 09
Email: bj@accequa.com
This information is information that Cyxone AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.25 CET on 20 June 2022.
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se.For more information, please visit www.cyxone.com